KALA

Kala Pharmaceuticals Inc.

Price

$0.53

return (12m)

-99.93%

p/e

0.01

p/bv

0.00

DIVIDEND YIELD

0.00%

KALA price

Kala Pharmaceuticals

If you had invested

exposure

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Return on Investment KALA

1 month

3 months

1 year

2 years

5 years

10 years

return

1 month

-29.50%

3 months

-74.49%

1 year

-99.93%

2 years

-99.82%

5 years

-99.99%

10 years

0.00%

Asset Comparator

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Fundamentals KALA

Valuation

P/E

0.01

Sector -3.77

Industry -3.77

P/BV

0.00

Sector 2.16

Industry 2.16

P/Revenue (PSR)

Sector 2.14

Industry 2.14

EV/EBITDA

4.55

Sector -219.67

Industry -219.67

EV/EBIT

4.55

Sector -46.02

Industry -46.02

P/EBITDA

0.00

Sector -22.58

Industry -22.58

P/EBIT

0.00

Sector -33.87

Industry -33.87

P/Total Assets

0.00

Sector 1.26

Industry 1.26

P/Net Current Assets

0.00

Sector -11.09

Industry -11.09

P/Working Capital

0.00

Sector -191.62

Industry -191.62

EPS

35.81

Sector -1.78

Industry -1.78

BVPS

121.95

Sector 2.05

Industry 2.05

Efficiency

Gross Margin

0.00%

Sector 40.85%

Industry 40.85%

EBITDA Margin

Sector -17,824.00%

Industry -17,824.00%

EBIT Margin

Sector -4,221,656.00%

Industry -4,221,656.00%

Operating Margin

0.00%

Sector -34.69%

Industry -34.69%

Net Profit Margins

0.00%

Sector -35.51%

Industry -35.51%

Asset Turnover

0.00

Sector 0.03

Industry 0.03

Profitability

ROE

29.37%

Sector -56.83%

Industry -56.83%

ROA

25.10%

Sector -60.12%

Industry -60.12%

ROIC

-359.10%

Sector -2,338.86%

Industry -2,338.86%

Dividends

Dividend yield

0.00%

Sector -

Industry -

Payout

0.00%

Sector -

Industry -

Debt

Current Ratio

6.88

Sector 2.89

Industry 2.89

Net Debt / EBITDA

4.57

Sector -14,697,933.03

Industry -14,697,933.03

Net Debt / EBIT

4.57

Sector -8.34

Industry -8.34

Net Debt / Equity

-0.80

Sector -34,400.71

Industry -34,400.71

Gross Debt / Equity

0.00

Sector -0.85

Industry -0.85

Equity/Assets

0.85

Sector 0.46

Industry 0.46

Liabilities/Assets

0.15

Sector 0.41

Industry 0.41

Growth

5Y Revenue CAGR

0.00%

Sector -

Industry -

5Y Earnings CAGR

0.00%

Sector -

Industry -

Fundamentals KALA

DRAG THE FRAME TO SEE MORE DATA

FAIR VALUE OF Kala Pharmaceuticals ACCORDING TO BENJAMIN GRAHAM

Graham's Fair Value

The Fair Value formula was created by Benjamin Graham to identify stocks with appreciation potential or that are being traded for less than they are worth. Graham was one of the greatest investors in history and Warren Buffett’s mentor.

Current price

$0.53

Fair Value

$313.46

Upside Return potential.

59,538.81%

See Graham's ranking

Because it considers equity value in its calculation, this formula may not work well for technology companies.

This is not a buy/sell recommendation; the fair value calculation takes into account only the formula created by Benjamin Graham, published in the book The Intelligent Investor.

Assets	Price (US$)	Return 12m	DY	P/E	P/BV	ROE	Net Profit Margins
KALA Kala Pharmaceuticals Inc.	$0.53	-99.93%	0.00%	0.01	0.00	29.37%	0.00%
JNJ Johnson & Johnson	$276.47	60.00%	1.90%	31.48	7.79	24.76%	21.48%
PFE Pfizer Inc.	$28.64	23.67%	6.01%	37.36	1.91	5.11%	6.86%
ABBV AbbVie Inc.	$257.20	25.27%	2.66%	72.11	-76.75	-106.44%	9.81%
NVO Novo Nordisk A/S	$46.74	-12.60%	3.97%	11.43	6.07	53.11%	35.32%
MRK Merck & Co. Inc.	$150.67	85.99%	2.24%	116.76	8.81	7.55%	4.76%
AZN AstraZeneca PLC	$162.57	1.81%	1.98%	19.30	4.97	25.77%	16.95%
BMY Bristol-Myers Squibb Company	$66.95	47.63%	3.75%	14.74	6.13	41.55%	18.85%
ZTS Zoetis Inc.	$75.67	-49.40%	2.76%	11.95	10.04	84.02%	27.77%
AMGN Amgen Inc.	$438.54	60.04%	2.25%	26.93	20.14	74.80%	22.95%
REGN Regeneron Pharmaceuticals Inc.	$834.48	47.70%	0.44%	19.82	2.71	13.65%	27.86%
HALO Halozyme Therapeutics Inc.	$110.01	47.03%	0.00%	31.19	89.88	288.13%	24.86%
MCK McKesson Corporation	$917.36	33.47%	0.36%	20.52	-28.15	-137.16%	1.29%
VRTX Vertex Pharmaceuticals Incorporated	$551.38	39.02%	0.00%	31.75	6.91	21.76%	35.00%
CAH Cardinal Health Inc.	$247.79	66.68%	0.83%	37.62	-21.79	-57.93%	0.62%
HRMY Harmony Biosciences Holdings Inc.	$42.15	12.31%	0.00%	13.47	2.44	18.14%	18.88%
ARGX argenx SE	$1,038.19	43.79%	0.00%	3.11	3.48	112.18%	44.41%

Stock vs Indice Comparison Tool

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

KALA Historical Dividends

current DY: 0.00%

5-year average DY: 0.00%

no dividend paid in the period.

ABOUT Kala Pharmaceuticals

Kala Pharmaceuticals Inc.

Average Investor10 user rating

4.0 (0 people)

United States

17 years

Founded: 2009

2017

Time since IPO - 9 years

188

Employees

Kala Pharmaceuticals Inc. (United States) is listed on the Nasdaq and has a market capitalization of $38.98 Thousand, with shareholders equity totaling $9.04 million.

The company employs approximately 188 people and operates in the Health Care sector, within the Biotechnology industry.

Over the past 12 months, Kala Pharmaceuticals Inc. reported $- in revenue, generating net income of $2.66 million.

Key financial metrics include a P/E ratio of 0.01, a price-to-book (P/B) ratio of 0.00, and a trailing twelve-month dividend yield of 0.00%.

The company trades under the ticker KALA.

Market cap

$38.98 Thousand

Net worth

$9.04 million

$9,044,000.00

Assets

$10.58 million

$10,582,000.00

Total Shares Outstanding

74.16 Thousand

74,000

Average Daily Trading Volume

Sector

Health Care

Industry

Biotechnology

KALA

KALA revenue and profits

Financial Results KALA

DRAG THE FRAME TO SEE MORE DATA

KALA cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more assets

BFRA - Biofrontera

$- -0,00% (12M)

P/E

0.00

0.00%

ROE

-893.55%

P/BV

0.00

MCK - McKesson

$917.36 34,00% (12M)

P/E

20.52

0.36%

ROE

-137.16%

P/BV

-28.15

CAH - Cardinal Health

$247.79 67,79% (12M)

P/E

37.62

0.83%

ROE

-57.93%

P/BV

-21.79

JNJ - Johnson & Johnson

$276.47 58,84% (12M)

P/E

31.48

1.90%

ROE

24.76%

P/BV

7.79

ABBV - AbbVie

$257.20 24,86% (12M)

P/E

72.11

2.66%

ROE

-106.44%

P/BV

-76.75

MRK - Merck & Co.

$150.67 83,76% (12M)

P/E

116.76

2.24%

ROE

7.55%

P/BV

8.81

AZN - AstraZeneca

$162.57 0,71% (12M)

P/E

19.30

1.98%

ROE

25.77%

P/BV

4.97

PFE - Pfizer

$28.64 23,22% (12M)

P/E

37.36

6.01%

ROE

5.11%

P/BV

1.91

BFRA - Biofrontera

$- -0,00% (12 M)

P/L

0.00

0.00%

ROE

-893.55%

P/VP

0.00

MCK - McKesson

$917.36 34,00% (12 M)

P/L

20.52

0.36%

ROE

-137.16%

P/VP

-28.15

CAH - Cardinal Health

$247.79 67,79% (12 M)

P/L

37.62

0.83%

ROE

-57.93%

P/VP

-21.79

JNJ - Johnson & Johnson

$276.47 58,84% (12 M)

P/L

31.48

1.90%

ROE

24.76%

P/VP

7.79

ABBV - AbbVie

$257.20 24,86% (12 M)

P/L

72.11

2.66%

ROE

-106.44%

P/VP

-76.75

MRK - Merck & Co.

$150.67 83,76% (12 M)

P/L

116.76

2.24%

ROE

7.55%

P/VP

8.81

AZN - AstraZeneca

$162.57 0,71% (12 M)

P/L

19.30

1.98%

ROE

25.77%

P/VP

4.97

PFE - Pfizer

$28.64 23,22% (12 M)

P/L

37.36

6.01%

ROE

5.11%

P/VP

1.91

Frequently Asked Questions

What is the price of Kala Pharmaceuticals (KALA) today?

A cotação de Kala Pharmaceuticals (KALA) hoje está em US$ 0.53, com uma variação de -99.93% em relação ao último ano. A cotação de Kala Pharmaceuticals (KALA) iniciou o ano negociando na casa dos US$ 0.56 e hoje está em US$ 0.53. Acompanhe o gráfico de cotação em tempo real, a cotação histórica de Kala Pharmaceuticals (KALA) e dados de ações do Ibovespa e mercados internacionais.

Quando Kala Pharmaceuticals (KALA) paga dividendos?

Kala Pharmaceuticals (KALA) não distribuiu dividendos no último ano.

Is Kala Pharmaceuticals (KALA) a good investment?

Atualmente, Kala Pharmaceuticals (KALA) está cotada a US$ 0.53, com um P/L de 0.01, representando um desvio de -57% em relação ao seu P/L médio histórico. No último ano, a ação apresentou uma variação de -99.93 em sua cotação e distribuiu US$ 0.00 em dividendos, resultando em um Dividend Yield de 0.00%. O retorno total do acionista foi de -99.93%.

Investors should keep in mind that past performance does not guarantee future results. This information is provided for educational purposes only and should not be considered investment advice.

How can I buy Kala Pharmaceuticals (KALA) stock?

Investir em ações de Kala Pharmaceuticals (KALA) pode ser feito de duas formas: comprando a stock uma empresa estrangeira e é atrelado ao dólar.

How much would 100 shares of Kala Pharmaceuticals (KALA) yield today?

A rentabilidade de Kala Pharmaceuticals (KALA) foi de -29.50% no último mês, -99.93% no último ano e -99.99% nos últimos 5 anos (já considerando valorização e dividendos).

Nos últimos 12 meses, a empresa pagou um total de US$ 0.00 em dividendos, um Dividend Yield de 0.00%.

Se você quisesse comprar 100 ações de Kala Pharmaceuticals (KALA) hoje, o investimento total seria de US$ 52.56, com base na cotação atual de US$ 0.53.

Based on historical performance, the investment would have grown to approximately:

Em 1 ano: US$ 0.04
Em 5 anos: US$ 0.005256
Em 10 anos: US$ 52.56

Past performance does not guarantee future results. This content is for informational purposes only and should not be considered investment advice.

KALA

Kala Pharmaceuticals Inc.

Price

return (12m)

p/e

p/bv

DIVIDEND YIELD

Return on Investment KALA

Valuation

Efficiency

Profitability

Dividends

Debt

Growth

Graham's Fair Value

COMPARING KALA WITH OTHER STOCK

current DY: 0.00%

5-year average DY: 0.00%

ABOUT Kala Pharmaceuticals

Kala Pharmaceuticals Inc.

United States

17 years

2017

188

PROFIT X PRICE KALA

Financial Results KALA

KALA cash flow

Asset, Revenue and Profit Growth - KALA

KALA balance sheet

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

Frequently Asked Questions